Trialmed Sp. z o.o.

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Graves' disease and hyperthyroidism3 trials
• Asthma1 trial
• Atopic dermatitis (eczema)1 trial
• Chronic spontaneous urticaria1 trial
• Hearing loss1 trial
• Hidradenitis suppurativa1 trial
• Lupus (SLE)1 trial
• Psoriasis1 trial

Phase

• Phase 27 trials
• Phase 32 trials
• Phase 41 trial

Status

• Completed4 trials
• Recruiting4 trials
• Active, not recruiting1 trial
• Withdrawn1 trial

Lead sponsor

• Immunovant Sciences GmbH2 trials
• Pfizer2 trials
• argenx1 trial
• AudioCure Pharma GmbH1 trial
• Lakefront Biotherapeutics NV1 trial
• and 3 more

Running trials

• Recruiting

  A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease

  2025-524001-33-00· Phase 2· Immunovant Sciences GmbH· Source

• Recruiting

  A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.

  NCT07596849· Phase 3· argenx· Source

• Active, not recruiting

  A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

  NCT07228390· Phase 2· Pfizer· Source

• Recruiting

  A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

  NCT07219615· Phase 2· Pfizer· Source

• Recruiting

  A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

  NCT07018323· Phase 2· Immunovant Sciences GmbH· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Graves' disease and hyperthyroidism3 recruiting
• Chronic spontaneous urticaria1 recruiting

Closed trials

• Recruiting

  A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT07711418· Phase 3· Nektar Therapeutics· Source

• Completed

  A Phase 2 study to evaluate the efficacy and safety of RPT193 in adults with moderate-to-severe T2-high asthma who are partially controlled on inhaled corticosteroid and long-acting beta 2 agonist therapy

  2022-502854-16-00· Phase 2· Rapt Therapeutics Inc.· Source

• Completed

  A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus

  NCT05856448· Phase 2· Lakefront Biotherapeutics NV· Source

• Completed

  Efficacy and Safety of AC102 Compared to Steroids in Adults With Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL)

  NCT05776459· Phase 2· AudioCure Pharma GmbH· Source

• Completed

  Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight

  NCT04306315· Phase 4· LEO Pharma· Source